Due to this gap, it may be worthwhile in the future to analyze APOE4’s impact on tau pathology in PD-related cognitive impairment and DLB using neuroimaging, given the prevalence of tau aggregation in these disorders, and APOE4’s known association with tau in AD. This evidence concerns the gene APOE and Parkinson disease.